Sanofi's Dengue vaccine succeeds in Phase III

|About: Sanofi (SNY)|By:, SA News Editor

Sanofi's (SNY) vaccine for Dengue fever met the primary goal of a Phase III study by reducing incidence of the illness by 56% in a trial involving over 10,000 children in Southeast Asia.

Dengue affects up to 100M people a year, mainly in tropical areas, and is caused by a virus that is carried by mosquitoes. Symptoms include severe fever and intense joint and muscle pain, and it can be fatal.

The success of the Phase III trial follows disappointing results in a Phase II study of 4,000 children, when Sanofi's vaccine only cut dengue cases by a worse-than-expected 30%.

Shares are +2% in Paris.